Nexalin Technology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NXL research report →
Price Chart
About the company
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia.
- CEO
- Mark White
- IPO
- 2022
- Employees
- 8
- HQ
- Houston, TX, US
Get TickerSpark's AI analysis on NXL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.30M
- P/E
- -0.31
- PEG
- -0.01
- P/S
- 15.20
- P/B
- 2.09
- EV/EBITDA
- -0.26
- Div Yield
- 0.00%
- Gross Margin
- -148.42%
- Op Margin
- -4202.54%
- Net Margin
- -4139.38%
- ROE
- -278.25%
- ROIC
- -600.62%
Latest fiscal year · YoY change
- Revenue
- $301.65K+78.8%
- Gross Profit
- $240.27K+81.8%
- Op Income
- $-8,390,881
- Net Income
- $-8,222,181-8.1%
- EPS
- $-15.00+39.8%
- OCF Growth
- -25.7%
- FCF Growth
- -20.5%
- 52W High
- $60.00
- 52W Low
- $4.00
- 50D MA
- $7.64
- 200D MA
- $12.64
- Beta
- 4.11
- RSI (14)
- 42
- Avg Volume
- 1.01M
No earnings-call transcripts are available for NXL yet.
- Free Float
- 80.9%
- Shares Outstanding
- 829.40K
- Float Shares
- 593.61K
of shares held by institutions
23 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Peak6 LLC | 240.21K | ▼ 144.25K |
| Vanguard Group Inc | 177.92K | ▲ 1.34K |
| Geode Capital Management, LLC | 139.58K | ▼ 107.45K |
| Vanguard Capital Management LLC | 126.54K | 0 |
| Citadel Advisors LLC | 75.40K | ▲ 75.40K |
| Jane Street Group, LLC | 65.50K | ▲ 54.99K |
| Vanguard Fiduciary Trust Co | 51.39K | 0 |
| State Street Corp | 32.30K | 0 |
| Ubs Group AG | 26.82K | ▲ 4.64K |
| Northern Trust Corp | 24.10K | 0 |
| Kovack Advisors, Inc. | 22.32K | ▼ 1.00K |
| Stonex Group Inc. | 13.50K | ▼ 9.43K |
Held by 7 ETFs
Biggest fund positions in NXL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 19, 25 | White Mark | other | 1,000,000 |
| Dec 19, 25 | Van Fleet Justin | other | 100,000 |
| Dec 19, 25 | Owens David | other | 1,000,000 |
| Dec 19, 25 | Shelton Carolyn Hamby | other | 100,000 |
| Dec 19, 25 | Hu Ben | other | 100,000 |
| Dec 19, 25 | Kazden Alan | other | 100,000 |
| Sep 29, 25 | OSSER LEONARD | other | 83,333 |
| Sep 29, 25 | Owens David | other | 36,459 |
| Sep 29, 25 | Hu Ben | other | 36,459 |
| Sep 29, 25 | Kazden Alan | other | 36,459 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NXL coverage
Recent articles, reports, and earnings notes.
No research on NXL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NXL report →Critical Survey: Enovis (NYSE:ENOV) vs. Nexalin Technology (NASDAQ:NXL)
defenseworld.net · Oct 6
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
globenewswire.com · Oct 1
Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy
globenewswire.com · Sep 29
LogicMark (OTCMKTS:LGMKD) vs. Nexalin Technology (NASDAQ:NXL) Head to Head Comparison
defenseworld.net · Sep 21
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study
globenewswire.com · Sep 3
Nexalin Technology Announces Reverse Stock Split
globenewswire.com · Aug 27
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company's Proprietary DIFS™ Platform
globenewswire.com · Jun 23
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
globenewswire.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.